Opaleye Management Inc. Buys $33K of Grace Therapeutics Inc (GRCE) — SEC Form 4, Nov 06, 2026
Open-Market Net Purchase · SEC Form 4
+$33,019
Equity position changed by +0.6%
Equity Position
3.05M sh
3,036,411 → 3,054,853
Equity Change
+0.6%
shares held after vs before
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Opaleye Management Inc. CIK 0001595855 |
10% Owner
|
Opaleye Management Inc. at Grace Therapeutics Inc
Full insider history
Bought (12 mo)
$676,929
Sold (12 mo)
—
More from this insider at Grace Therapeutics Inc
| 2026-11-19 | Buy | +$83,435 | View |
| 2026-10-26 | Buy | +$158,601 | View |
| 2026-10-21 | Buy | +$8,001 | View |
| 2026-10-17 | Buy | +$136,178 | View |
| 2026-10-13 | Buy | +$29,683 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF2F1F5 | 2026-11-03 | P - Purchase | 10,328 A | $1.79 | +$18,481 | 3,046,739 | Indirect By Opaleye, L.P. |
| Common Stock, par value $0.0001 per shareF3F1F5 | 2026-11-04 | P - Purchase | 5,027 A | $1.80 | +$9,060 | 3,051,766 | Indirect By Opaleye, L.P. |
| Common Stock, par value $0.0001 per shareF4F1F5 | 2026-11-05 | P - Purchase | 3,087 A | $1.77 | +$5,478 | 3,054,853 | Indirect By Opaleye, L.P. |
Footnotes (5)
- F1
- Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Show more
- F2
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.775 to $1.79. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. Show more
- F3
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.81. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. Show more
- F4
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.77 to $1.78. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. Show more
- F5
- Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Show more
Related filings at Grace Therapeutics Inc
Institutional Holders
13F holders · Sep 30, 2026
38
institutional managers reporting a position
Largest by reported value
- Opaleye Management Inc. $6.02M
- Cerity Partners Llc $1.83M
- Eversept Partners, Lp $1.66M
5%+ Holders · 13D/G
3 filers
Other insiders at Grace Therapeutics Inc
GET /v1/forms/4/0001493152-26-050313
API docs
View Original SEC Filing